Nextcure, Inc. (NXTC) fundamentals score
Nextcure is a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies, including antibody-drug conjugates (“ADCs”).
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 3.3 out of 10, Unhealthy fundamentals
- Growth: 3.5/10
- Profitability: 1.0/10
- Financial health: 6.6/10
- Earnings quality: 4.5/10
- Valuation: 1.5/10
Scores are calculated from Nextcure, Inc.’s SEC filings, using the 12 months through 2020-12. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10